Table 4.
Treatment responses among different inhalation therapies in FEV1%pred <50% group*
| Total | LAMA | LABA + LAMA | LABA + ICS | LABA + LAMA + ICS | P-value | |
|---|---|---|---|---|---|---|
|
Total number of participants
|
1687 |
267 (15.8) |
184 (10.9) |
138 (8.2) |
1098 (65.1) |
|
|
Exacerbations, MD (IQR)
|
0 (0–1) |
0 (0–2) |
0 (0–1) |
0 (0–2) |
0 (0–1) |
<0.001 |
|
Exacerbations
|
|
|
|
|
|
<0.001 |
| Yes |
642 (39.2) |
128 (49.2) |
64 (35.8) |
61 (44.9) |
389 (36.6) |
|
| No |
997 (60.8) |
132 (50.8) |
115 (64.2) |
75 (55.1) |
675 (63.4) |
|
|
Frequent exacerbations
|
|
|
|
|
|
<0.001 |
| Yes |
1296 (79.1) |
184 (70.8) |
154 (86) |
100 (73.5) |
858 (80.6) |
|
| No |
343 (20.9) |
76 (29.2) |
25 (14) |
36 (26.5) |
206 (19.4) |
|
|
Hospitalisations, MD (IQR)
|
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0.718 |
|
Hospitalisations
|
|
|
|
|
|
0.758 |
| Yes |
1245 (76.0) |
200 (76.9) |
141 (78.8) |
103 (75.7) |
801 (75.3) |
|
| No |
394 (24.0) |
60 (23.1) |
38 (21.2) |
33 (24.3) |
263 (24.7) |
|
|
All-cause mortality
|
|
|
|
|
|
0.838 |
| Yes |
48 (2.8) |
7 (2.6) |
5 (2.7) |
2 (1.4) |
34 (3.1) |
|
| No |
1639 (97.2) |
260 (97.4) |
179 (97.3) |
136 (98.6) |
1064 (96.9) |
|
|
Prescription outcomes
|
|
|
|
|
|
0.087 |
| Adjust treatment |
342 (20.3) |
64 (24) |
26 (14.1) |
28 (20.3) |
224 (20.4) |
|
| Continuous using | 1345 (79.7) | 203 (76) | 158 (85.9) | 110 (79.7) | 874 (79.6) |
FEV1%pred – forced expiratory volume in the first-second percentage of predicted, ICS – inhaled corticosteroid, IQR – interquartile range, LABA – long-acting β2-agonist, LAMA – long-acting muscarinic antagonist, MD – median
*Presented as n (%) unless specified otherwise.